Juan Wu

Also affiliated with Nanjing University of Information Science and Technology, Emmes (United States), Suzhou Municipal Hospital, Third Affiliated Hospital of Zhengzhou University

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “The results of multicenter phase II, double-blind placebo-controlled trial of maintenance ixazomib after allogeneic hematopoietic cell transplantation (alloHCT) for high-risk multiple myeloma (MM) from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 1302).”.

The results of multicenter phase II, double-blind placebo-controlled trial of maintenance ixazomib after allogeneic hematopoietic cell transplantation (alloHCT) for high-risk multiple myeloma (MM) from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 1302).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.7003

N/A

0DataRank · unranked

2 citations

Qaiser Bashir, Marcelo C. Pasquini, Michael J. Martens, Juan Wu, Melissa Alsina +11 more

A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial

Transplantation and Cellular Therapy(2022)10.1016/j.jtct.2022.07.007

N/A

0DataRank · unranked

9 citations

T Nishihori, Marcelo C. Pasquini, Michael J. Martens, Juan Wu, Melissa Alsina +15 more